Literature DB >> 15476255

Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells.

Leonie M van Duivenvoorde1, Pascale Louis-Plence, Florence Apparailly, Ellen I H van der Voort, Tom W J Huizinga, Christian Jorgensen, René E M Toes.   

Abstract

OBJECTIVE: Dendritic cells (DCs) are crucial for the initiation of T cell immunity and therefore play an important role in the initiation and regulation of immune responses in arthritis. Full mobilization of effector T cells depends on the proper maturation of DCs. Current evidence indicates that the type of T cell response induced is crucially dependent on the activation status of the DCs. In this study, we explored the immunologic effects of differentially matured DCs on the development of collagen-induced arthritis (CIA).
METHODS: Bone marrow-derived DCs were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF). Before immunization with bovine type II collagen (CII) protein, mice were repeatedly injected with DCs that had been pulsed with CII. Immature, semimature, or fully mature DCs were injected. Mice were boosted on day 21 after CII immunization, and the disease course was monitored.
RESULTS: While vaccination with immature or lipopolysaccharide-activated DCs had no significant effect on the disease course, administration of antigen-loaded, tumor necrosis factor (TNF)-modulated DCs propagated in GM-CSF with or without interleukin-4 resulted in a delayed onset of arthritis and a lower clinical score. The response was antigen-specific, since TNF-treated DCs pulsed with a control antigen did not modify the disease course. A specific decrease in the collagen-specific "Th1-associated" IgG2a response was observed, whereas IgG1 titers were unaffected.
CONCLUSION: CIA can be prevented through vaccination with TNF-matured DCs in an antigen-specific manner. These findings provide a rationale for immunotherapy using DCs in rheumatoid arthritis. Copyright 2004 American College of Rheumatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476255     DOI: 10.1002/art.20513

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  25 in total

1.  TGF-beta-treated antigen presenting cells suppress collagen- induced arthritis through the promotion of Th2 responses.

Authors:  Sundo Jung; Yoon-Kyung Park; Hyunji Lee; Jung Hoon Shin; Gap Ryol Lee; Se-Ho Park
Journal:  Exp Mol Med       Date:  2010-03-31       Impact factor: 8.718

Review 2.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells.

Authors:  Sandrine Rullé; Marie-Dominique Ah Kioon; Carine Asensio; Julie Mussard; Hang-Korng Ea; Marie-Christophe Boissier; Frédéric Lioté; Géraldine Falgarone
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 4.  Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs.

Authors:  Claudia Mauri; Natalie Carter
Journal:  Arthritis Res Ther       Date:  2009-08-04       Impact factor: 5.156

5.  TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model.

Authors:  Nasreen Vohra; Monique Verhaegen; Lisa Martin; Amy Mackay; Shari Pilon-Thomas
Journal:  Cancer Immunol Immunother       Date:  2010-05       Impact factor: 6.968

6.  CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis.

Authors:  Hongmei Li; Guang-Xian Zhang; Youhai Chen; Hui Xu; Denise C Fitzgerald; Zhao Zhao; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 7.  Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.

Authors:  Shailesh R Satpute; Malarvizhi Durai; Kamal D Moudgil
Journal:  Semin Arthritis Rheum       Date:  2008-01-04       Impact factor: 5.532

8.  LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells.

Authors:  Amy E Anderson; David J Swan; Bethan L Sayers; Rachel A Harry; Angela M Patterson; Alexei von Delwig; John H Robinson; John D Isaacs; Catharien M U Hilkens
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

Review 9.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

10.  Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis.

Authors:  Louise J Healy; Helen L Collins; Stephen J Thompson
Journal:  Open Rheumatol J       Date:  2008-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.